221 related articles for article (PubMed ID: 19190907)
21. Evaluation of widely consumed botanicals as immunological adjuvants.
Ragupathi G; Yeung KS; Leung PC; Lee M; Lau CB; Vickers A; Hood C; Deng G; Cheung NK; Cassileth B; Livingston P
Vaccine; 2008 Sep; 26(37):4860-5. PubMed ID: 18640165
[TBL] [Abstract][Full Text] [Related]
22. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial.
Sabbatini PJ; Kudryashov V; Ragupathi G; Danishefsky SJ; Livingston PO; Bornmann W; Spassova M; Zatorski A; Spriggs D; Aghajanian C; Soignet S; Peyton M; O'Flaherty C; Curtin J; Lloyd KO
Int J Cancer; 2000 Jul; 87(1):79-85. PubMed ID: 10861456
[TBL] [Abstract][Full Text] [Related]
23. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.
Ragupathi G; Coltart DM; Williams LJ; Koide F; Kagan E; Allen J; Harris C; Glunz PW; Livingston PO; Danishefsky SJ
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13699-704. PubMed ID: 12359877
[TBL] [Abstract][Full Text] [Related]
24. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
MacLean GD; Reddish MA; Koganty RR; Longenecker BM
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of synthetic conjugates of Lewis(y) oligosaccharide with proteins in mice: towards the design of anticancer vaccines.
Kudryashov V; Kim HM; Ragupathi G; Danishefsky SJ; Livingston PO; Lloyd KO
Cancer Immunol Immunother; 1998 Feb; 45(6):281-6. PubMed ID: 9490197
[TBL] [Abstract][Full Text] [Related]
26. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.
Slovin SF; Ragupathi G; Fernandez C; Jefferson MP; Diani M; Wilton AS; Powell S; Spassova M; Reis C; Clausen H; Danishefsky S; Livingston P; Scher HI
Vaccine; 2005 May; 23(24):3114-22. PubMed ID: 15837210
[TBL] [Abstract][Full Text] [Related]
27. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
Theilacker C; Coleman FT; Mueschenborn S; Llosa N; Grout M; Pier GB
Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.
Pan Y; Chefalo P; Nagy N; Harding C; Guo Z
J Med Chem; 2005 Feb; 48(3):875-83. PubMed ID: 15689172
[TBL] [Abstract][Full Text] [Related]
29. Comparative immunological studies of tumor-associated Lewis X, Lewis Y, and KH-1 antigens.
Guo J; Jiang W; Li Q; Jaiswal M; Guo Z
Carbohydr Res; 2020 Jun; 492():107999. PubMed ID: 32272238
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
[TBL] [Abstract][Full Text] [Related]
31. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.
Krug LM; Ragupathi G; Hood C; Kris MG; Miller VA; Allen JR; Keding SJ; Danishefsky SJ; Gomez J; Tyson L; Pizzo B; Baez V; Livingston PO
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6094-100. PubMed ID: 15447995
[TBL] [Abstract][Full Text] [Related]
32. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.
Gathuru JK; Koide F; Ragupathi G; Adams JL; Kerns RT; Coleman TP; Livingston PO
Vaccine; 2005 Sep; 23(39):4727-33. PubMed ID: 15978705
[TBL] [Abstract][Full Text] [Related]
33. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
[TBL] [Abstract][Full Text] [Related]
34. Stereoselective Synthesis of Sialyl Lewis
Rashidijahanabad Z; Ramadan S; O'Brien NA; Nakisa A; Lang S; Crawford H; Gildersleeve JC; Huang X
Angew Chem Int Ed Engl; 2023 Nov; 62(47):e202309744. PubMed ID: 37781858
[TBL] [Abstract][Full Text] [Related]
35. Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity.
Sawada R; Sun SM; Wu X; Hong F; Ragupathi G; Livingston PO; Scholz WW
Clin Cancer Res; 2011 Mar; 17(5):1024-32. PubMed ID: 21343375
[TBL] [Abstract][Full Text] [Related]
36. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray.
Oyelaran O; Gildersleeve JC
Proteomics Clin Appl; 2010 Mar; 4(3):285-94. PubMed ID: 21137049
[TBL] [Abstract][Full Text] [Related]
38. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
[TBL] [Abstract][Full Text] [Related]
39. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Adv Exp Med Biol; 1994; 353():105-24. PubMed ID: 7527178
[TBL] [Abstract][Full Text] [Related]
40. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice.
Kudryashov V; Glunz PW; Williams LJ; Hintermann S; Danishefsky SJ; Lloyd KO
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3264-9. PubMed ID: 11248067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
